127 related articles for article (PubMed ID: 35188049)
1. Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy.
Tan JY; Qiu TY; Chiang J; Tan YH; Yang VS; Chang EWY; Poon E; Somasundaram N; Farid M; Tao M; Lim ST; Chan JY
Leuk Lymphoma; 2023 Mar; 64(3):586-596. PubMed ID: 35188049
[TBL] [Abstract][Full Text] [Related]
2. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Alderuccio JP; Olszewski AJ; Evens AM; Collins GP; Danilov AV; Bower M; Jagadeesh D; Zhu C; Sperling A; Kim SH; Vaca R; Wei C; Sundaram S; Reddy N; Dalla Pria A; D'Angelo C; Farooq U; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Kassam S; Yazdy M; Rabinovich E; Post FA; Varma G; Karmali R; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein A; Blum KA; Boughan KM; Mian A; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Maliske SM; Epperla N; Caimi P; Smith SE; Kamdar M; Venugopal P; Feldman TA; Rector D; Smith SD; Stadnik A; Portell CA; Lin Y; Naik S; Montoto S; Lossos IS; Cwynarski K
Blood Adv; 2021 Jul; 5(14):2852-2862. PubMed ID: 34283175
[TBL] [Abstract][Full Text] [Related]
3. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
[TBL] [Abstract][Full Text] [Related]
4. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Ferreri AJM; Angelillo P; Erbella F; Cattaneo C; Verga L; Lleshi A; Allione B; Ponzoni M; Facchetti F; Pagani C; Foppoli M; Pecciarini L; Sassone M; Steffanoni S; Flospergher E; Rossi G; Spina M; Re A
Blood Adv; 2022 Nov; 6(22):5811-5820. PubMed ID: 35580327
[TBL] [Abstract][Full Text] [Related]
9. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
Noy A; Lee JY; Cesarman E; Ambinder R; Baiocchi R; Reid E; Ratner L; Wagner-Johnston N; Kaplan L;
Blood; 2015 Jul; 126(2):160-6. PubMed ID: 25957391
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
[TBL] [Abstract][Full Text] [Related]
11. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China: A Retrospective Single-Center Study.
Liu R; Zhao H; Xiao G; Tao Y; Tang X; Feng L; Liao B; Liu B; Guan J; Li L; Chen Z; He H; You H
Technol Cancer Res Treat; 2024; 23():15330338231214236. PubMed ID: 38179657
[No Abstract] [Full Text] [Related]
13. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.
Lim KJC; Di Ciaccio P; Polizzotto MN; Milliken S; Cochrane T; Goh Z; Shaw B; Perry E; Gilbertson M; Kermode W; Cheah CY; Latimer M; Hamad N; Ku M
Br J Haematol; 2023 Jun; 201(5):865-873. PubMed ID: 36866733
[TBL] [Abstract][Full Text] [Related]
15. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Zayac AS; Evens AM; Danilov A; Smith SD; Jagadeesh D; Leslie LA; Wei C; Kim SH; Naik S; Sundaram S; Reddy N; Farooq U; Kenkre VP; Epperla N; Blum KA; Khan N; Singh D; Alderuccio JP; Godara A; Yazdy MS; Diefenbach C; Rabinovich E; Varma G; Karmali R; Shao Y; Trabolsi A; Burkart M; Martin P; Stettner S; Chauhan A; Choi YK; Straker-Edwards A; Klein A; Churnetski MC; Boughan KM; Berg S; Haverkos BM; Orellana-Noia VM; D'Angelo C; Bond DA; Maliske SM; Vaca R; Magarelli G; Sperling A; Gordon MJ; David KA; Savani M; Caimi P; Kamdar M; Lunning MA; Palmisiano N; Venugopal P; Portell CA; Bachanova V; Phillips T; Lossos IS; Olszewski AJ
Haematologica; 2021 Jul; 106(7):1932-1942. PubMed ID: 33538152
[TBL] [Abstract][Full Text] [Related]
17. Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
Malecek MK; Petrich AM; Rozell S; Chu B; Trifilio S; Galanina N; Maurer M; Farooq U; Link BK; Nowakowski GS; Nabhan C; Ayed AO
Am J Hematol; 2017 Nov; 92(11):1156-1162. PubMed ID: 28719025
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
19. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
[TBL] [Abstract][Full Text] [Related]
20. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
